CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLYM CLIMB BIO INC

Market Closed 05-29 16:00:00 EDT

10.96

-0.38

-3.35%

盘后10.65

-0.31-2.83%

19:32 EDT

High11.56	Low10.86	Vol605.21K
Open11.24	D1 Closing11.34	Amplitude6.17%
Mkt Cap627.58M	Tradable Cap411.61M	Total Shares57.26M
T/O6.72M	T/O Rate1.61%	Tradable Shares37.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":10.96,"timestamp":1780084800000,"preClose":11.34,"halted":0,"volume":605207,"hourTrading":{"tag":"盘后","latestPrice":10.65,"preClose":10.96,"latestTime":"19:32 EDT","volume":5893,"amount":64405.8085,"timestamp":1780097554561,"change":-0.31,"changeRate":-0.028285,"amplitude":0.028285},"delay":0,"changeRate":-0.03350970017636676,"floatShares":37555400,"shares":57260500,"eps":-0.789373,"marketStatus":"Market Closed","change":-0.38,"latestTime":"05-29 16:00:00 EDT","open":11.24,"high":11.56,"low":10.86,"amount":6719236,"amplitude":0.061728,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.789373,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":11.34,"preHourTrading":{"tag":"盘前","latestPrice":11.34,"preClose":11.34,"latestTime":"09:25 EDT","volume":10023,"amount":114386.575407,"timestamp":1780061134809,"change":0,"changeRate":0,"amplitude":0.133157},"postHourTrading":{"tag":"盘后","latestPrice":10.65,"preClose":10.96,"latestTime":"19:32 EDT","volume":5893,"amount":64405.8085,"timestamp":1780097554561,"change":-0.31,"changeRate":-0.028285,"amplitude":0.028285},"volumeRatio":0.8193545557481732,"impliedVol":1.3138,"impliedVolPercentile":0.4382},"requestUrl":"/m/hq/s/CLYM","defaultTab":"news","newsList":[{"id":"2639714672","title":"BRIEF-Climb Bio - Files For Resale Of Up To 11.6 Million Shares Of Common Stock By Selling Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2639714672","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639714672?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:11","pubTimestamp":1780085462,"startTime":"0","endTime":"0","summary":"BRIEF-Climb Bio - Files For Resale Of Up To 11.6 Million Shares Of Common Stock By Selling StockholdersMay 29  - Climb Bio Inc CLYM.O:CLIMB BIO - FILES FOR RESALE OF UP TO 11.6 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS- SEC FILINGFurther company coverage: CLYM.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nFWN4260X3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639567221","title":"Climb Bio - Files for Resale of up to 11.6 Mln Shares of Common Stock by Selling Stockholders- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2639567221","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639567221?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:07","pubTimestamp":1780085258,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nFWN4260X3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638445175","title":"H.C. Wainwright Sticks to Their Buy Rating for Climb Bio (CLYM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638445175","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638445175?lang=en_us&edition=fundamental","pubTime":"2026-05-27 01:55","pubTimestamp":1779818112,"startTime":"0","endTime":"0","summary":"In a report released today, Ram Selvaraju from H.C. Wainwright maintained a Buy rating on Climb Bio, with a price target of $20.00. According to Ti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638167565","title":"Climb Bio presents initial Phase 1 data for CLYM116 in healthy volunteers at ERA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638167565","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638167565?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:05","pubTimestamp":1779793535,"startTime":"0","endTime":"0","summary":"Climb Bio flagged upcoming data presentations at the European Renal Association Congress in Glasgow on June 3-6, 2026.Initial Phase 1 safety findings for CLYM116 in healthy volunteers will be presented on June 5.PK/PD modeling for CLYM116 to support development in IgA nephropathy will also be presented at the meeting.A trial-in-progress update will outline PrisMN, an ongoing Phase 2 study of budoprutug in primary membranous nephropathy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL4t6dgj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636898531","title":"Analysts Are Bullish on These Healthcare Stocks: Climb Bio (CLYM), ArriVent BioPharma, Inc. (AVBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636898531","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636898531?lang=en_us&edition=fundamental","pubTime":"2026-05-20 07:10","pubTimestamp":1779232231,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Climb Bio (CLYM) and ArriVent BioPharma, Inc. (AVBP)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-climb-bio-clym-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-climb-bio-clym-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSG","BK4137","LU0029874061.USD","LU0128526141.USD","BK4539","AVBP","BK4581","BK4139","XBI","LABU","BK4585","BK4588","BK4112","BLSX","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635441117","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Climb Bio (CLYM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635441117","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635441117?lang=en_us&edition=fundamental","pubTime":"2026-05-15 00:50","pubTimestamp":1778777405,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR) and Climb Bio (CLYM) wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-and-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-and-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4581","BK4585","CLYM","BK4139","LU0029874061.USD","XLV","HCSG","XBI","BK4539","VYGR","LABU","LU0128526141.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634218555","title":"Climb Bio Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2634218555","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634218555?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:57","pubTimestamp":1778583420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 06:57 ET (10:57 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634904862","title":"Climb Bio, Inc. : H.c. Wainwright Raises Target Price to $20 From $15","url":"https://stock-news.laohu8.com/highlight/detail?id=2634904862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634904862?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:41","pubTimestamp":1778582462,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nAZN4SVPK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633452348","title":"Climb Bio Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2633452348","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633452348?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:57","pubTimestamp":1778248620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 09:57 ET (13:57 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633452933","title":"Climb Bio price target raised to $17 from $15 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2633452933","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633452933?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:46","pubTimestamp":1778247965,"startTime":"0","endTime":"0","summary":"Wedbush raised the firm’s price target on Climb Bio (CLYM) to $17 from $15 and keeps an Outperform rating on the shares. With Climb Bio recently co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/climb-bio-price-target-raised-to-17-from-15-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/climb-bio-price-target-raised-to-17-from-15-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633128635","title":"Climb Bio Q1 EPS $(0.20) Beats $(0.29) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633128635","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633128635?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:27","pubTimestamp":1778160459,"startTime":"0","endTime":"0","summary":"Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 35.48 percent increase over losses of $(0.31) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52366958/climb-bio-q1-eps-0-20-beats-0-29-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CLYM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633146512","title":"Climb Bio plans multiple-dose study of budoprutug subcutaneous formulation in autoimmune patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2633146512","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633146512?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:17","pubTimestamp":1778152666,"startTime":"0","endTime":"0","summary":"Climb Bio highlighted completed Phase 1 results for subcutaneous budoprutug in healthy volunteers, showing B-cell depletion comparable to intravenous dosing, supporting a planned multiple-dose study in autoimmune patients.Initial readouts from ongoing budoprutug trials are scheduled for 2026, led by low-dose cohort data in immune thrombocytopenia expected in June, followed by early primary membranous nephropathy signals in Q4.CLYM116 modeling and initial Phase 1 safety data are set for presentation at ERA 2026 in June, with initial Phase 1 PK/PD data expected mid-2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL4YV1b4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CLYM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633217113","title":"Climb Bio price target raised to $19 from $8 at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2633217113","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633217113?lang=en_us&edition=fundamental","pubTime":"2026-05-07 15:48","pubTimestamp":1778140134,"startTime":"0","endTime":"0","summary":"BTIG raised the firm’s price target on Climb Bio (CLYM) to $19 from $8 and keeps a Buy rating on the shares. The company’s anti-CD19 mAb has multip...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/climb-bio-price-target-raised-to-19-from-8-at-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/climb-bio-price-target-raised-to-19-from-8-at-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633282131","title":"Wedbush Adjusts Price Target on Climb Bio to $15 From $14, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2633282131","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633282131?lang=en_us&edition=fundamental","pubTime":"2026-05-06 22:17","pubTimestamp":1778077022,"startTime":"0","endTime":"0","summary":"Climb Bio (CLYM) has an average rating of buy and mean price target of $18.69, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLYM","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633139656","title":"Analysts Offer Insights on Healthcare Companies: DaVita (DVA), IQVIA Holdings (IQV) and Climb Bio (CLYM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633139656","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633139656?lang=en_us&edition=fundamental","pubTime":"2026-05-06 21:32","pubTimestamp":1778074327,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on DaVita (DVA), IQVIA Holdings (IQV) and Climb Bio (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-davita-dva-iqvia-holdings-iqv-and-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-davita-dva-iqvia-holdings-iqv-and-climb-bio-clym-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1201861249.SGD","LU0130103400.USD","BK4588","LU0130518102.USD","LU0648000940.SGD","BK4139","LU1989764664.SGD","LU1201861165.SGD","LU0130517989.USD","LU1791710582.SGD","XLV","LABU","BK4530","BK4539","BK4559","BK4585","LU0648001328.SGD","LU0882574055.USD","LU0528227936.USD","LU0198837287.USD","LU0477156797.USD","LU0130102774.USD","LU0477156953.USD","BK4581","BK4196","LU1989764748.USD","LU1261432733.SGD","XBI","DVA","BK4121","IQV","CLYM","LU1791710400.SGD","LU0980610538.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633972464","title":"Climb Bio Inc : Leerink Partners Raises Target Price to $15 From $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2633972464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633972464?lang=en_us&edition=fundamental","pubTime":"2026-05-06 11:00","pubTimestamp":1778036407,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nFWN41I195:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633692800","title":"Climb Bio Initiated at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2633692800","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633692800?lang=en_us&edition=fundamental","pubTime":"2026-05-06 03:06","pubTimestamp":1778007960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 15:06 ET (19:06 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLYM","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914019","title":"Climb Bio reports Phase 1 budoprutug subcutaneous data supports patient trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914019","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914019?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:08","pubTimestamp":1777979296,"startTime":"0","endTime":"0","summary":"Climb Bio disclosed topline Phase 1 results showing budoprutug subcutaneous dosing produced B-cell depletion comparable to intravenous administration in healthy volunteers, supporting continued development.Safety profile was described as generally acceptable, backing plans to move subcutaneous dosing into autoimmune disease patients.Clinical trials in primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus remain on track, with first ITP data expected in June.Initial readouts from pMN and SLE studies are slated for Q4 2026, setting up multiple clinical catalysts tied to dosing strategy and broader expansion across B-cell mediated diseases.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL37yPN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BN0W2T93.GBP","BK4588","SG9999014039.USD","BK4139","BK4539","BK4112","CLYM","IE00BN0W2V16.EUR","NDAQ","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633911838","title":"Chardan Initiates Climb Bio at Buy With $22 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2633911838","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633911838?lang=en_us&edition=fundamental","pubTime":"2026-05-05 18:44","pubTimestamp":1777977892,"startTime":"0","endTime":"0","summary":"Climb Bio (CLYM) has an average rating of buy and mean price target of $16.69, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLYM","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633992044","title":"U.S. RESEARCH ROUNDUP-Applied Materials, Axsome Therapeutics, Onsemi","url":"https://stock-news.laohu8.com/highlight/detail?id=2633992044","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633992044?lang=en_us&edition=fundamental","pubTime":"2026-05-05 15:07","pubTimestamp":1777964820,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Applied Materials, Axsome Therapeutics, OnsemiMay 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL4N41I0F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WGS","COIN","MZTI","BR","KNSL","PLTR","EVER","INSP","CRCL","ACMR","CRWG","ICHR","NCLH","DDOG","TGT","DT","AEIS","PLTY","DUOL","RYAN","PLOO","GPI","RBLX","PINS","FLGT","DOGD","CRWV","GBTG","LSCC","ICOI","HUBB","AXSM","CORD","CNO","COIW","ESPR","LRCX","RBA","H","PLTU","APD","CHD","CONX","AMAT","PLTW","ARE","CBRE","CLYM","CVX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eliemtx.com","stockEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":0.2483},{"period":"3month","weight":0.5329},{"period":"6month","weight":4.7989},{"period":"1year","weight":7.9836},{"period":"ytd","weight":1.74}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.012175},{"month":2,"riseRate":0.6,"avgChangeRate":0.088588},{"month":3,"riseRate":0.2,"avgChangeRate":-0.090224},{"month":4,"riseRate":0.8,"avgChangeRate":0.28834},{"month":5,"riseRate":0.6,"avgChangeRate":0.068848},{"month":6,"riseRate":0.25,"avgChangeRate":-0.069889},{"month":7,"riseRate":0.75,"avgChangeRate":0.07628},{"month":8,"riseRate":0.25,"avgChangeRate":0.096778},{"month":9,"riseRate":0.2,"avgChangeRate":-0.124516},{"month":10,"riseRate":0.4,"avgChangeRate":-0.049478},{"month":11,"riseRate":0,"avgChangeRate":-0.130257},{"month":12,"riseRate":0.6,"avgChangeRate":0.177771}],"exchange":"NASDAQ","name":"CLIMB BIO INC","nameEN":"CLIMB BIO INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CLIMB BIO INC(CLYM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CLIMB BIO INC,CLYM,CLIMB BIO INC股票,CLIMB BIO INC股票老虎,CLIMB BIO INC股票老虎国际,CLIMB BIO INC行情,CLIMB BIO INC股票行情,CLIMB BIO INC股价,CLIMB BIO INC股市,CLIMB BIO INC股票价格,CLIMB BIO INC股票交易,CLIMB BIO INC股票购买,CLIMB BIO INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CLIMB BIO INC(CLYM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction